This stock is bleeding cash but keeps raising it. The reverse split and constant offerings scream desperation. 📉 Technically, it's oversold (RSI 38) and stuck below both WMAs—a classic downtrend. The "exclusive" webinars feel like a sideshow. Until the ops deliver, this is a hard pass.

Verdict: SELL. #FallingKnife

"Boom! Calidi Biotherapeutics is firing on all cylinders with their cancer-fighting gene therapy buzz 🧬. The stock just went supernova—RSI at 91 (overbought alert!), but that WMA crossover screams momentum. Volume? Astronomical. This is either a moonshot or a classic 'buy the rumor' frenzy. Chart’s got a wild Hammer pattern, but tread carefully—this rocket could either orbit or fizzle. High-risk, high-reward play: BUY for the brave, but keep a tight stop! 🚀 #BiotechBets"

Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing immunotherapies for the treatment of cancer. It engages in advancing a potent allogeneic stem cell capable of carrying an anti-tumor payload for use in multiple oncology indications, including high-grade gliomas and solid tumors. The company's cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Its pipeline of products candidates in the clinic includes NeuroNova that are allogeneic neural stem cells loaded with an oncolytic adenovirus for the treatment of high-grade gliomas; and SuperNova, which are allogeneic adipose-derived mesenchymal stem cells loaded with tumor-selective CAL1 oncolytic vaccinia virus for the treatment of advanced metastatic solid tumors. The company was founded in 2014 and is based in San Diego, California.

Calidi Biotherapeutics, Inc. CLDI: 0.185 USD

Bullish views

Bearish views